Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results

被引：0

作者：

Armstrong, April W. ^{[1
]}

Lebwohl, Mark ^{[2
]}

Warren, Richard B. ^{[3
,4
]}

Sofen, Howard ^{[5
]}

Imafuku, Shinichi ^{[6
]}

Ohtsuki, Mamitaro ^{[7
]}

Spelman, Lynda ^{[8
]}

Passeron, Thierry ^{[9
]}

Papp, Kim A. ^{[10
,11
]}

Kisa, Renata M. ^{[12
]}

Berger, Victoria ^{[12
,13
]}

Vritzali, Eleni

Hoyt, Kim ^{[12
]}

Colombo, Matthew J. ^{[12
]}

Banerjee, Subhashis ^{[12
]}

Strober, Bruce ^{[14
]}

Thaci, Diamant ^{[15
]}

Blauvelt, Andrew ^{[16
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA

[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[3] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, England

[4] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England

[5] Univ Calif Los Angeles, Sch Med & Dermatol Res Associates, Los Angeles, CA USA

[6] Fukuoka Univ, Fac Med, Fukuoka, Japan

[7] Jichi Med Univ, Tochigi, Japan

[8] Verac Clin Res, Brisbane, Qld, Australia

[9] Univ Cote Azur, Univ Hosp Nice, Nice, France

[10] Alliance Clin Res & Prob Med Res, Waterloo, ON, Canada

[11] Univ Toronto, Toronto, ON, Canada

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Bristol Myers Squibb, Sissach, Switzerland

[14] Yale Univ, New Haven, CT USA

[15] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[16] Oregon Med Res Ctr, Portland, OR USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0261

引用

页码：509 / 511

页数：3

共 50 条

[11] Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation
Potestio, Luca
Tommasino, Nello
Lauletta, Giuseppe
Feo, Federica
Ruggiero, Angelo
Martora, Fabrizio
Portarapillo, Antonio
Guerriero, Luigi
Megna, Matteo
EXPERT OPINION ON DRUG SAFETY, 2024, 23 (06) : 677 - 685
[12] DEUCRAVACITINIB EFFICACY IN SPECIAL AREAS OF SCALP, FINGERNAILS, AND PALMS/SOLES IN PLAQUE PSORIASIS: RESULTS FROM A PHASE 3 TRIAL
Bissonnette, Robert
Armstrong, April W.
Elewski, Boni
Kisa, Renata M.
Colombo, Matthew J.
Ye, Cynthia
Banerjee, Subhashis
Blauvelt, Andrew
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[13] Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study
Okubo, Yukari
Ohtsuki, Mamitaro
Morita, Akimichi
Yamaguchi, Masako
Shima, Tomohiro
Tani, Yumiko
Nakagawa, Hidemi
JOURNAL OF DERMATOLOGY, 2019, 46 (03): : 186 - 192
[14] Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials
Armstrong, April W.
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Morita, Akimichi
Paul, Carle
Papp, Kim A.
Colombo, Matthew J.
Scotto, Julie
Vaile, John
Zhuo, Joe
Vritzali, Eleni
Berger, Victoria
Schroeder, Georgene
Banerjee, Subhashis
Thaci, Diamant
Strober, Bruce
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
[15] One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial
Strober, Bruce
Gold, Linda Stein
Bissonnette, Robert
Armstrong, April W.
Kircik, Leon
Tyring, Stephen K.
Piscitelli, Stephen C.
Brown, Philip M.
Rubenstein, David S.
Tallman, Anna M.
Lebwohl, Mark G.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 800 - 806
[16] Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years
Strober, Bruce
Sofen, Howard
Imafuku, Shinichi
Paul, Carle
Gooderham, Melinda
Spelman, Lynda
Seo, Seong Jun
Passeron, Thierry
Kisa, Renata M.
Berger, Victoria
Vritzali, Eleni
Hoyt, Kim
Colombo, Matthew J.
Banerjee, Subhashis
Augustin, Matthias
Gold, Linda Stein
Alexis, Andrew
Thaci, Diamant
Blauvelt, Andrew
Lebwohl, Mark
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2247 - 2249
[17] The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis
Zhang, L.
Guo, L.
Wang, L.
Jiang, X.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (11) : 1937 - 1946
[18] Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years An Open-Label Extension of Randomized Clinical Trials
Armstrong, April W.
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Ohtsuki, Mamitaro
Spelman, Lynda
Passeron, Thierry
Papp, Kim A.
Kisa, Renata M.
Vaile, John
Berger, Victoria
Vritzali, Eleni
Hoyt, Kim
Colombo, Matthew J.
Scotto, Julie
Banerjee, Subhashis
Strober, Bruce
Thaci, Diamant
Blauvelt, Andrew
JAMA DERMATOLOGY, 2025, 161 (01) : 56 - 66
[19] Deucravacitinib (DEUC) Long-Term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Study Program
Thaci, Diamant
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Paul, Carle
Szepietowski, Jacek
Spelman, Lynda
Passeron, Thierry
Colston, Elizabeth
Hippeli, Lauren
Napoli, Andrew
Kisa, Renata
Banerjee, Subhashis
Menter, Alan
Blauvelt, Andrew
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 120 - 121
[20] Deucravacitinib in plaque psoriasis: a profile of its use
Lee, Arnold
DRUGS & THERAPY PERSPECTIVES, 2023, 39 (11) : 357 - 364

← 1 2 3 4 5 →